CA3158607A1 - Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies - Google Patents

Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Info

Publication number
CA3158607A1
CA3158607A1 CA3158607A CA3158607A CA3158607A1 CA 3158607 A1 CA3158607 A1 CA 3158607A1 CA 3158607 A CA3158607 A CA 3158607A CA 3158607 A CA3158607 A CA 3158607A CA 3158607 A1 CA3158607 A1 CA 3158607A1
Authority
CA
Canada
Prior art keywords
antigen
antibody
binding fragment
ctla
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3158607A
Other languages
English (en)
French (fr)
Inventor
John KURLAND
Alejandra NEGRO
Shao-Chun Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CA3309448A priority Critical patent/CA3309448A1/en
Publication of CA3158607A1 publication Critical patent/CA3158607A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3158607A 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies Pending CA3158607A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3309448A CA3309448A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
US63/023,554 2020-05-12
PCT/EP2021/062695 WO2021228978A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3309448A Division CA3309448A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Publications (1)

Publication Number Publication Date
CA3158607A1 true CA3158607A1 (en) 2021-11-18

Family

ID=75977756

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3158607A Pending CA3158607A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
CA3309448A Pending CA3309448A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3309448A Pending CA3309448A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Country Status (12)

Country Link
US (3) US20210355224A1 (enExample)
EP (1) EP4021940A1 (enExample)
JP (2) JP7387912B2 (enExample)
KR (1) KR20230009354A (enExample)
CN (1) CN114729054A (enExample)
AU (3) AU2021269832B2 (enExample)
BR (1) BR112022021893A2 (enExample)
CA (2) CA3158607A1 (enExample)
IL (3) IL328607A (enExample)
MX (1) MX2022006728A (enExample)
TW (2) TWI870592B (enExample)
WO (1) WO2021228978A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260077026A1 (en) * 2022-09-07 2026-03-19 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트
TW202617179A (zh) * 2024-06-13 2026-05-01 大陸商江蘇恆瑞醫藥股份有限公司 抗pd-l1抗體和抗ctla-4抗體聯合治療腫瘤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180079814A1 (en) * 2015-04-01 2018-03-22 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
JP7085709B2 (ja) * 2016-06-20 2022-06-17 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌ１及びｌａｇ－３に結合する結合分子
JP2019537619A (ja) * 2016-09-27 2019-12-26 オンコロジー、インコーポレイテッド β２−糖タンパク質１のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ
KR20200020662A (ko) * 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
AU2018273988C1 (en) * 2017-05-26 2025-11-13 Bruin Biosciences, Inc. Chemoembolization agents
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US20210260051A1 (en) * 2018-06-14 2021-08-26 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
CA3102334A1 (en) * 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Also Published As

Publication number Publication date
KR20230009354A (ko) 2023-01-17
TWI870592B (zh) 2025-01-21
AU2024202963A1 (en) 2024-05-30
IL297640A (en) 2022-12-01
IL297640B1 (en) 2026-07-01
WO2021228978A1 (en) 2021-11-18
US20210355224A1 (en) 2021-11-18
MX2022006728A (es) 2022-06-09
US20220363762A1 (en) 2022-11-17
JP2024016209A (ja) 2024-02-06
AU2024266949A1 (en) 2024-12-19
BR112022021893A2 (pt) 2022-12-20
AU2021269832A1 (en) 2022-05-19
TW202535468A (zh) 2025-09-16
CN114729054A (zh) 2022-07-08
TW202207976A (zh) 2022-03-01
IL311936A (en) 2024-06-01
AU2021269832B2 (en) 2024-09-19
EP4021940A1 (en) 2022-07-06
JP2023524359A (ja) 2023-06-12
JP7387912B2 (ja) 2023-11-28
AU2024202963B2 (en) 2025-11-20
US20240239893A1 (en) 2024-07-18
CA3309448A1 (en) 2026-06-21
IL328607A (en) 2026-07-01

Similar Documents

Publication Publication Date Title
JP6499971B2 (ja) 抗ｃｄ３８抗体及びレナリドマイドを含む組成物
US20240239893A1 (en) Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
CN120053637A (zh) 抗dll3药剂的给药方案
EP4512421A1 (en) Drug combination of anti-tim-3 antibody and anti-pd-1 antibody
AU2021369590A1 (en) Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
CA3221817A1 (en) Combination therapies for the treatment of cancer
US20240317854A1 (en) Methods for treating cancer with anti-ilt3 antibodies
WO2025002263A1 (zh) 治疗组合及其用途和治疗方法
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
TW202502813A (zh) 包含偶聯物的藥物組合的治療方法和用途
AU2023336562A1 (en) Compositions and methods for treating advanced solid tumors
EA050171B1 (ru) Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек
BR122025009416A2 (pt) Combinação farmacêutica compreendendo um anticorpo anti-pd-l1 e um anticorpo anti-ctla-4, seu uso, uso de um anticorpo anti-pd-l1, uso de um anticorpo anti-ctla-4 e composição
CN113117072A (zh) 喹啉衍生物与pd-1单抗的药物组合
WO2023174278A1 (zh) 抗tim-3抗体与去甲基化药物的药物组合
WO2025087358A1 (zh) 抗体药物偶联物用于治疗癌症的方法
HK40069657A (en) Anti-galectin-9 antibodies and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240423

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250424

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D16-D106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PARAGRAPH 84(1)(A) OF THE PATENT RULES

Effective date: 20250508

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PARAGRAPH 84(1)(A) OF THE PATENT RULES

Effective date: 20250508

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250508

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250508

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250617

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250617

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250709

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251028

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251216

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251216

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251231

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260422

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260429

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260527

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260527

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260527

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260721

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260721